Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 3, 2007, Pages 235-242

  Irvin, Charles G ^a   Kaminsky, David A ^a   Anthonisen, Nicholas R ^b   Castro, Mario ^c   Hanania, Nicola A ^d   Holbrook, Janet T ^e   Lima, John J ^f   Wise, Robert A ^g,h  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c School of Medicine   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Children's Clinic   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Antiasthmatic agents; Bronchodilator agents; Clinical trial; Multicenter studies

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MONTELUKAST; PLACEBO; THEOPHYLLINE;

ADD ON THERAPY; ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; INSOMNIA; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEBULIZER; NERVOUSNESS; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VOMITING;

ACETATES; ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY FLOW RATES; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG; MALE; MIDDLE AGED; QUINOLINES; SEVERITY OF ILLNESS INDEX; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 33846829665     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200603-416OC     Document Type: Article

References (42)

1. National Asthma Education and Prevention Program Expert Panel. Report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; 1997. NIH Publication No. 97-4051.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health; 2003. NIH Publication No. 02-3659.
3. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996;334:1380-1388.
4. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-818.
5. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-1418.
6. Ukena D, Harnest U, Sakalaukas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-2760.
7. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes P. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000;55:817-841.
8. Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151-159.
9. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systemic review of current evidence. BMJ 2002;329:1545-1551.
10. Ram FSF, Cates CJ, Ducharme FM. Long-acting beta2 agonists versus anti-leukotriene as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005;1:CD003137.
11. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-844.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
13. Juniper E, O'Byrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-907.
14. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-621.
15. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multi attribute Asthma Symptom Utility Index. Chest 1998;114:998-1007.
16. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-38.
17. Oh C, Kim J, Kearns B, Cheng A, Dobashi T. A rate turbidimetric immunoassay for theophylline using biotin-avidin system. Clin Chim Acta 1993;218:59-71.
18. Amin RD, Cheng H, Rogers JD. Determination of MK-0476 in human plasma by liquid chromatography. J Pharm Biomed Anal 1995;13:155-158.
19. American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001;345:1529-1536.
20. McCullagh P, Nelder J. Generalized linear models. New York: Chapman & Hall; 1989.
21. Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13.
22. Dupont WD, Plummer WD. Power and sample size calculations: a review and computer program. Control Clin Trials 1990;11:116-128.
23. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcok IM, Barnes PJ. Amolecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99:8921-8926.
24. Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP. Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. Chest 1996;109:963-968.
25. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol 1996;77:34-38.
26. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-1735.
27. Condino-Neto A, Vilela MM, Cambiucci EC, Ribeiro JD, Guglielmi AA, Magna LA, De Nucci G. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br J Clin Pharmacol 1991;32:557-561.
28. Umeda M, Ichiyama T, Hasegawa S, Kaneko M, Matsubara T, Furukawa S. Theophylline inhibits NF-kappaB activation in human peripheral blood mononuclear cells. Int Arch Allergy Immunol 2002;128:130-135.
29. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Am J Respir Crit Care Med 1995;151:1907-1914.
30. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-1008.
31. Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Ching KF, Barnes P. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-276.
32. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392-396.
33. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-1112.
34. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet J-C, Peszek I, Zhang JI, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-1868.
35. Bjermer L, Bisgaard H, Bouquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Dass SB, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial. BMJ 2003;327:891.
36. Ducharme FM. Inhaled glucocorticoid versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;136:621.
37. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, Seidenberg BC, Reiss TF. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999;130:487-495.
38. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-1095. [Published erratum appears in J Allergy Clin Immunol 2001;107:614.]
39. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, Bateman ED. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97:234-241.
40. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
41. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-912.
42. Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005;353:2637-2639.